Compare Southwest Airlines Co (LUV) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Southwest Airlines Co vs Novavax Inc — how do they compare? Southwest Airlines Co trades at $41.41 (market cap $20.41B), while Novavax Inc trades at $11.11 (market cap $1.85B). The key difference: Southwest Airlines Co is far larger — about 11× Novavax Inc's market cap, and Southwest Airlines Co pays a 1.73% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Southwest Airlines Co for 65 Days and Novavax Inc for 59 Days on average.
| LUV | NVAX | |
|---|---|---|
Market Cap | $20.41B | $1.85B |
Volume | 4,706,365 | 8,362,562 |
Sector | Industrials | Health |
52-Week High | $54.80 | $12.56 |
52-Week Low | $29.67 | $6.22 |
Typical Hold Time | 65 Days | 59 Days |
Enterprise Value | $23.51B | $1.43B |
Dividend Yield | 1.73% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Southwest Airlines (LUV) trades at $41.72, down 1.72% today, with mixed technical signals showing bearish moving averages but neutral oscillators. The company shows improving fundamentals with revenue growth from $28.06B in 2025 to projected $30.1B in 2026, though net margins remain thin at 2.78%. Recent earnings show volatility with a Q2 2026 beat but Q1 2026 miss, while analyst consensus leans slightly bullish with a $49.61 price target representing 19% upside potential.
LUV presents a transformation story with new revenue initiatives driving growth, but faces headwinds from high fuel costs and competitive pressures. The stock offers value with reasonable P/E of 26.08 and P/S of 0.73, though investors should monitor execution of commercial initiatives and fuel cost management. Near-term catalyst includes Q3 2026 earnings release on October 21, 2026.
Novavax (NVAX) trades at $11.22, down 0.88% on the day, with a bullish technical signal from moving averages and strong analyst support (74% buy ratings). The company shows mixed fundamentals with a positive P/E of 3.14 and EV/EBITDA of 1.72, but negative net income margin of -59.87% and negative shareholder equity. Recent developments include regulatory approvals for its updated COVID-19 vaccine and strategic pivot toward Matrix-M adjuvant licensing partnerships.
The outlook remains speculative with significant execution risks in the transition from COVID vaccine dependency to partnership-driven model. While valuation metrics appear attractive and technical momentum is positive, persistent negative cash flows and competitive pressures in the biotech sector warrant caution. The stock presents high-risk, high-reward potential for investors comfortable with biotech volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Southwest Airlines Co
Southwest Airlines is the largest domestic carrier in the United States, as measured by the number of originating passengers boarded. Southwest operates over 700 aircraft in an all-Boeing 737 fleet. Despite expanding into longer routes and business travel, the airline still specializes in short-haul leisure flights, using a point-to-point network. Southwest operates a low-cost carrier business model.
Read more on LUV →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
